Shots:

• The P-III (ELEVATE-TN) trial evaluating Calquence as monothx. or in combination with obinutuzumab vs chlorambucil + obinutuzumab in a ratio (1:1:1) in 535 patients with CLL
• The results showed a PFS & OS benefit, 89% reduction in risk of disease progression or death in combination at a median follow-up of 58.2mos. & 79% as monothx; patients were alive (90% & 84% vs 82%) @5yrs., OS data are immature & the relative risk for death was 45%
• In the P-III (ASCEND) trial, Calquence showed a sustained PFS benefit @4yr., patients were alive (62%) @42mos. vs 19% with IdR/BR.3, median follow-up (46.5mos. vs 45.3mos.). The safety & tolerability in both trials were consistent with earlier findings with no new safety signals

Ref: AstraZeneca | Image: AstraZeneca